Yutrepia (treprostinil) for pulmonary hypertension

Last updated June 3, 2025, by Lindsey Shapiro, PhD
Fact-checked by Jose Lopes, PhD

What is Yutrepia for pulmonary hypertension?

Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil that’s approved in the U.S. to improve exercise capacity in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) associated with interstitial lung disease, known as PH-ILD.

In PH, an elevated pressure in the blood vessels of the lungs makes it harder for the heart to pump blood. Yutrepia’s active ingredient, treprostinil, mimics the activity of a naturally occurring hormone called prostacyclin that helps blood vessels relax and widen. This is expected to improve blood flow through the lungs, thereby easing disease symptoms and making exercise easier.

The treatment, from Liquidia, was optimized for deep lung delivery via an easy-to-use and low-effort inhalation device. According to the developer, because the medication does not depend on strong inhalation to be dispersed, it could be an advantageous treprostinil formulation for people with limited inhalation abilities or diminished lung capacity.

Therapy snapshot

Who can take Yutrepia?

Yutrepia is approved in the U.S. for improving exercise ability in people with PAH and PH-ILD, corresponding to groups 1 and 3 in the World Health Organization’s classification system.

There are no contraindications for Yutrepia’s use, per its label.

How is Yutrepia administered?

Yutrepia is delivered directly to the lungs via an inhaler device and is indicated for use three to five times per day. The medication comes in capsules containing a dry powder that is loaded into the provided inhalation device. Each capsule can be inhaled in two breaths.

The recommended starting dose depends on whether a person has never before used treprostinil or if they’ve previously used Tyvaso, an inhaled treprostinil solution. Dose adjustments can be subsequently made as needed and tolerated, with a target maintenance dose of 79.5-106 micrograms, four times daily.

Patients will need to be trained on the administration process for Yutrepia — specifically, regarding dosing, inhaler preparation, administering the medication, maintenance, and cleaning — before starting treatment.

Yutrepia in clinical trials

Yutrepia’s approval in the U.S. was based on two Phase 3 clinical trials of Tyvaso, as well as an open-label Phase 3 study of Yutrepia in adults with PAH:

• The TRIUMPH 1 (NCT00147199) trial showed that Tyvaso led to improvements in exercise abilities and life quality when compared with a placebo in adults with PAH who were also using the oral therapies bosentan (sold as Tracleer) or sildenafil (sold as Revatio). This study involved more than 200 people with idiopathic (no known cause), heritable, or connective tissue disease-associated PAH who had New York Heart Association functional class III symptoms.
• A study dubbed INCREASE (NCT02630316) demonstrated that Tyvaso similarly improved exercise capacity among adults with PH-ILD, and was associated with lower rates of clinical worsening than a placebo. This trial enrolled PH-ILD patients with lung diseases such as idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, and connective tissue disease.
• The INSPIRE trial (NCT03399604) testing Yutrepia showed that the treatment stabilized or improved exercise abilities and life quality in adults with PAH who were new to this class of treatments, as well as those who switched to it from Tyvaso.

An ongoing observational study called ASCENT (NCT06129240) is now evaluating Yutrepia’s safety and tolerability in adults with PH-ILD.

Yutrepia side effects

The most common side effects associated with Yutrepia are:

• cough
• headache
• throat irritation
• dizziness.

Yutrepia may also cause:

• low blood pressure (hypotension) symptoms, especially in people with existing hypotension
• an increased risk of bleeding, especially in people using blood thinners
• bronchospasms, or narrowing of the airways that cause breathing difficulties.

People at an elevated risk of bronchospasm, including those with asthma, chronic obstructive pulmonary disease, or other causes of airway sensitivity, should optimally be treated for the existing airway disease before and during Yutrepia treatment. Patients should always seek medical care if they have trouble breathing while using Yutrepia.

Certain other medications could affect treprostinil exposure, impacting its safety or efficacy. Patients should tell their healthcare team about all medications they use.

Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.